Clinuvel Pharmaceuticals Ltd. - Sponsored ADR CUVL
—
5.63
(0.15)
(2.60%)
as of 25 Sep
- Market cap
- $291.5M
- P/E
- —
Follow CUVL
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.79 | 4.67 | 6.15 | 12.75 | 7.40 | 15.33 | 9.17 | 8.76 | 7.05 | 6.00 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 6.92 | 7.17 | 16.62 | 27.80 | 20.23 | 31.44 | 21.09 | 19.98 | 11.40 | 9.00 |
High Price
|
|||
| — | — | — | — | — | — | — | — | — | 104 |
Employees
|
|||
| — | — | — | — | — | — | — | — | — | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | — | — | EBT | |||
| — | — | — | — | — | — | — | — | — | — | EBT Margin | |||
| — | — | — | — | — | — | — | — | — | 0 |
Net Income
|
|||
| — | — | — | — | — | — | — | — | — | — | Depreciation | |||
| — | — | — | — | — | — | — | — | — | — | Revenue/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Earnings/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Cash Flow/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Capex/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Free CF/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Book Value/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Shares | |||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | — | — | Op' Cash Flow | |||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| — | — | — | — | — | — | — | — | — | — | FCF | |||
| — | — | — | — | — | — | — | — | — | — | Working Cap' | |||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | — | — | — | Net Debt | |||
| — | — | — | — | — | — | — | — | — | — | Sh' Equity | |||
| — | — | — | — | — | — | — | — | — | — | ROA | |||
| — | — | — | — | — | — | — | — | — | — | ROIC | |||
| — | — | — | — | — | — | — | — | — | — | ROE | |||
predictions in italic, sparklines do not include predictions
Clinuvel Pharmaceuticals Ltd. - Sponsored ADR (CUVL) Latest News
27 Aug
A decade of profitability provides foundation for CLINUVEL’s U.S. expansion
CLINUVEL has posted a decade of profitability that now underpins planned U.S. expansion. Sustained profits enable major U.S. market entry that can materially lift revenue trajectory.
23 Jul
CLINUVEL implements strategic reorganisation to refocus on U.S. markets
Clinuvel Pharmaceuticals Ltd. implements strategic reorganisation to refocus on U.S. markets. Strategic reorganisation to refocus on U.S. markets signals major shift likely to alter company trajectory.